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Abstract Chromosomal microarray analysis (CMA) for un-
explained anomalies and developmental delay has improved
diagnosis rates, but results classified as variants of uncertain
significance (VUS) may challenge both clinicians and fami-
lies. We explored the impact of such results on families, in-
cluding parental knowledge, understanding and interpretation.
Semi-structured telephone interviews were conducted with
parents (N=14) who received genetic counseling for a VUS
in their child. Transcripts were analyzed through an iterative
coding process. Participants demonstrated a range of recall
and personal interpretation regarding whether test results pro-
vided a causal explanation for their children’s health issues.
Participants maintained contradictory interpretations, describ-
ing results as answers while maintaining that little clarification
of their child’s condition had been provided. Reported benefits
included obtaining medical services and personal validation.
Parents described adaptation/coping processes similar to those
occurring after positive test results. Recall of terminology,
including BVUS^ and precise CMA abnormalities, was poor.
However, most demonstrated conceptual understanding of
scientific uncertainty. All participants expressed intentions to
return for recommended genetics follow-up but had miscon-
ceptions about how this would occur. These results provide
insight into the patient-and-family experience when receiving
uncertain genomic findings, emphasize the importance of ex-
ploring uncertainty during the communication process, and
highlight areas for potential attention or improvement in the
clinical encounter.
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Introduction
Chromosomal microarray analysis (CMA) to detect copy
number variations (CNVs) is used as a first-tier diagnostic
genetic test for individuals with unexplained congenital anom-
alies or developmental disabilities (Manning et al. 2010; Mill-
er et al. 2010a). The identification of a genetic disorder can
provide information to families and care providers regarding
prognosis, medical management, and reproductive decision-
making (Lopez-Rangel et al. 2008). In well-defined chromo-
somal deletion/duplication syndromes, clinical management
may include referrals to other health care providers based on
risks for associated medical complications and follow-up in
genetics clinic at recommended intervals. In the absence of
such a diagnosis, determining appropriate follow-up and man-
agement may be more challenging.
Due to large gaps in knowledge of the phenotypic effects of
many CNVs, the interpretation of array results can be prob-
lematic (Coughlin et al. 2012). Given their novelty and lack of
functional data for the majority of genes, it is not uncommon
for CMA results to be classified as variants of uncertain clin-
ical significance (VUS) (Lee et al. 2007). In some cases, pa-
rental testing may help to clarify whether a CNV is benign or
pathogenic (Shaffer et al. 2008), but if parental samples are
unavailable or uninformative and there is limited description
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of the CNV in the medical literature, interpretation of results is
often consistent with a VUS (Manning et al. 2010). This
Bgenetic ambiguity^ can be difficult for families to process.
They are confronted with a genetic test result that may not
provide an explanation for their child’s condition, leaving
them with uncertainty regarding a diagnosis.
There is a wide body of literature, spanning several de-
cades, surrounding diagnostic uncertainty in pediatric illness.
The vast majority focuses on parental attitudes, stress, coping,
and adaptation to a lack of diagnosis for their ill children
(Lipinski et al. 2006; Reiff et al. 2012; Whitmarsh et al.
2007). While such studies are relevant to the provision of
genetic counseling for results of uncertain significance, they
focus on parents’ psychological response to genetic diagno-
ses, or lack thereof, rather than their understanding of an in-
herently uncertain finding.
Uncertainty in the setting of a genetic diagnosis is a more
recent area of exploration (Lipinski et al. 2006; Whitmarsh
et al. 2007), although little research has been conducted to
determine how parents interpret and utilize a VUS. Since par-
ents have certain expectations as to what a genetic diagnosis
will mean for their family, such as the anticipation of an ex-
planation (Lewis et al. 2010;Michie et al. 1997) and improved
medical management (Graungaard and Skov 2007; Lewis
et al. 2010; Lopez-Rangel et al. 2008; Michie et al. 1997;
Rosenthal et al. 2001), exploring uncertainty in this context
may help to ensure better understanding and adaptation to
ambiguity. A study exploring parental response to CMA re-
sults identified themes of incomplete comprehension and
struggles to derive personal meaning among parents whose
children had received a pathogenic or a VUS CMA result
(Reiff et al. 2012). When examining preferences for results
from microarrays, Turbitt et al. (2014) found respondents fa-
vored knowing about variants for their potential practical ben-
efits, though they also agreed that such results would raise
parental anxiety (Turbitt et al. 2014). A recent study assessed
parental understanding, perceived value, perceptions of child
vulnerability, and parental stress after receiving a VUS (Jez
et al. 2015). While findings were consistent with ongoing
difficulties with ambiguity, perceptions that the VUS had pro-
vided some explanation and relief were also noted. Questions
still remain about the parental effort to adapt to and cope with
the diagnostic ambiguity of a VUS.
Purpose of the Study
The purpose of this exploratory qualitative study was to fur-
ther investigate the interpretation and impact of genetic test
results of uncertain significance in the context of pediatric
chromosomal microarray analysis. A better understanding of
patients’ and families’ perspectives on ambiguous test results
and their impact on care management plans is crucial to pro-
viding effective genetic counseling services, especially as we
enter the era of genomic sequencing (Ali-Khan et al. 2009;
Fanos 2012; Miller et al. 2010b).
Methods
Participants
Families of children who underwent chromosomal microarray
analysis through the Michigan Medical Genetics Laboratories
(MMGL) at the University of Michigan Health System
(UMHS) and received genetic counseling for a CMA VUS
at the UMHS Pediatric Genetics clinic between February
2011 and March 2013 were eligible for inclusion. This
timeframe was chosen in order to minimize recall bias while
still providing a large enough sample for recruitment. During
this period, the Pediatric Genetics clinic was staffed by up to
three genetic counselors and six pediatric geneticists. Families
entered the CMA counseling session as either established pa-
tients of the Pediatric Genetics clinic, in which case testing
was ordered by a Pediatric Genetics provider, or as new pa-
tients, in which case testing had been ordered by another sub-
specialist at UMHS. For established Pediatric Genetics pa-
tients, initial results disclosure usually occurred prior to the
counseling session in the form of a phone conversation. For
new patients, there was a variety of disclosure formats, e.g.,
phone or in-person conversation with a non-geneticist. A typ-
ical CMA counseling session included a discussion between
the child’s parent(s), one of the genetic counselors, and/or one
of the geneticists. Topics discussed included the CMAVUS,
its implications, and recommended follow-up evaluations. A
letter summarizing this discussion was sent to both the family
and the referring physician following the appointment for both
new and returning patients.
Instrumentation
A semi-structured interview guide was developed specifically
for this study based on available literature in the subject area,
supplemented by anecdotal experience of clinical genetic
counselors. Open-ended questions with follow-up prompts
assessed parental recall of the test result, personal understand-
ing and interpreted meaning(s) of the test result, emotional
response and adjustment to receiving the test result, interpre-
tation of parental test results (if performed), motivation to
follow up with recommended return visits to the genetics clin-
ic and other referrals, and reflections on the helpfulness of
genetic counseling (see example questions in Table 1). This
interview guide was piloted with pediatric genetic counselors.
It was not piloted with parents from the target study popula-
tion, given the knowledge that the population was small and
concerns regarding response rate and expected sample size of
study interviews.
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Table 1 Condensed Codebooka with Example Questions from Interview Guide
Domainb Thematic content areas Sub-themes Example questions
Pre-CMA testing How did you and your child end up
in the genetics clinic?
Coping How important was it to you to have
a diagnosis for your child’s health issues?
Diagnostic odyssey
Parental Recall & Understanding Comprehension of CMA Do you recall what this test was looking for?
How testing works
Reason for testing
Parental Recall & Understanding Comprehension of results
Recall of result Do you recall the result of the test?
Self-rated understanding Can you tell me more about your own
personal understanding of the result?
Self-rated genetics knowledge
Recall of VUS terminology Do you remember the counselor or doctor
discussing uncertain significance?
Scientific uncertainty
Impact of results Impact of results Did this information change anything for you?
Access to services
Information
Emotional impact What emotions do you remember experiencing
when you received/discussed the test result?
Impact of results Coping Did the information change your ability to deal
with your child’s health?
Empowerment
Engagement
Acceptance
Optimism/Pessimism
Family support
Parental interpretation Interpretation of result Do you feel that the genetic change found
through this testing explains
your child’s health issues?
Provides an answer
Is the cause
Meaning not clear
Lack of resolution
Limits of prognostic information What does this result say to you about
your child’s future?
Genetics Follow-up Follow-up in genetics What role will the genetics clinic play in your
child’s medical care going forward?
Motivation Do you plan to go back to the genetics
clinic in the future?
Anticipation of future information
Ongoing provider expertise
Understanding of reason for follow-up
Patient satisfaction
Staff communication
Staff supportiveness
Suggestions for improvement
a Individual codes N=130
b Thematic content areas not assigned to a domain are not presented in this paper
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Procedures
Parents of children who received genetic counseling for a
CMAVUSwere identified by review of a databasemaintained
by MMGL and mailed an invitation to participate in the study
as well as a mail-back response card to indicate interest. Ad-
ditionally, from October-December 2012, parents were re-
cruited prospectively during the CMA VUS counseling ses-
sion; in these cases, at the end of the counseling session, par-
ents were provided with a copy of the same invitation mate-
rials and response card. Only one parent of each child was
eligible to participate. There were no other inclusion or exclu-
sion criteria specified for participation. Participants were of-
fered a $15 gift card in appreciation of their time. This study
was approved by the Institutional Review Board at the Uni-
versity of Michigan Medical School (HUM#00062486).
Semi-structured interviews were conducted over the tele-
phone by one author (L.A.K.). The author conducting the
interview was not part of the clinical care team for any of
the participants. Some of the study team had provided clinical
genetic counseling to the families of parents interviewed;
however, each interview and corresponding transcript was
assigned a numeric identifier. Personal identifiers were re-
moved from the transcripts in an effort to conceal the identity
of the interview subject to the study team when reviewing the
data.
Data Analysis
Interviews were recorded and transcribed verbatim. Each in-
terview was linked to the specific VUS result(s) for the child.
Transcripts were analyzed for cross-cutting themes through an
iterative group coding process (DeCuir-Gunby et al. 2011).
The authors met on a weekly or bi-weekly basis to review
coding progress, compare coded samples, and work toward
consensus. Half of the transcripts (7/14) were coded and
discussed by all authors to identify and resolve coding dis-
crepancies and for codebook revisions. Upon reaching full
group consensus on these transcripts, one author (K.M.O.)
independently re-coded the seven initial transcripts using the
final version of the codebook. One author (L.A.K.) indepen-
dently coded the remaining transcripts and reviewed them
with the other authors to ensure that full group agreement
was achieved.
Many thematic content areas (domains) were identified
in the transcripts (Table 1). We chose to highlight 4 do-
mains having relevance for counseling for genomic testing
and selected 21 quotations from 8 of the 14 participants
which were felt to be illustrative for presentation. Other
quotations, although usually consistent with the selections,
were not chosen for a variety of reasons, such as length,
clarity, and/or fluency.
Results
Participant Characteristics
Parents of 55 children were identified as eligible and invited to
participate. Fourteen parents representing 14 different families
were interviewed (participation rate 25 %). Interviews ranged
in length from 23 to 77min (average 48min). The participants
included parents of patients with a wide range of indications
for genetic testing, including multiple congenital anomalies,
developmental delay/autism, behavioral concerns, and chron-
ic medical conditions. Themajority of parents were Caucasian
females who had completed at least a high school education
(Table 2). The average time between results disclosure and
phone interviews was 6.4 months (range 1–15 months).
Nine of 14 participants’ children underwent CMA after
meeting with a member of the pediatric genetics team. The
remaining 5 participants had testing ordered by the UMHS
Division of Pediatric Neurology and were referred for genetic
counseling after an abnormality was detected.
Themes Identified in Interview Responses
The number of responses coded as consistent with a particular
theme are provided in parentheses below. It is important to
note that the numbers do not always equal the total sample
size due to contradictory statements made by participants.
Parental Recall and Understanding
Parental comprehension of the testing process and results was
explored by assessing recall and eliciting participants’ self-
rated understanding. Several parents could not recall the pur-
pose of testing, stating that they proceeded with testing be-
cause a physician requested it (n=8). Others considered the
reason for testing to be Bto rule out medical problems^ and did
not specifically mention chromosomes or genetic conditions.
Some felt confident in their self-rated comprehension prior to
receiving results (n=5), while others reported that they had
failed to grasp the details of testing (n=3 with partial under-
standing, n=5 with absent understanding). For some, this re-
lated to a self-reported lack of genetic literacy. Most parents
could not specify that CMA identifies CNVs; some thought
that the test involved DNA sequencing.
While 3 of 14 parents were able to report their child’s CMA
result accurately, including specific chromosomal bands, most
only recalled that there was extra or missing material; 7 re-
membered which chromosome, while 1 reported an incorrect
chromosome and 3 did not remember. Another mother incor-
rectly reported the results of parental testing as negative when,
in fact, the variant had been maternally inherited.
Similarly, participants’ self-rated understanding of test re-
sults varied widely between complete (n=3), partial (n=6),
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and absent (n=4). Several reported that they did not initially
comprehend results at all (e.g., at the time of phone disclosure)
but understood following in-person disclosure and discussion
with the doctor/genetic counselor. Others were still not confi-
dent in their grasp of test results several months after in-person
appointments. When asked how she explained to others what
the testing indicated, one mother responded:
BI say she’s got a genetic, um… abnormality on chro-
mosome 15… And they’re like, what? And it doesn’t
really make sense to anyone, and it doesn’t really make
any sense to me either.^ (Participant 13)
Despite 12 of 14 participants reporting that they did not
recall the use of the term Buncertain significance^ –
terminology consistently used during visits as well as in writ-
ten summary letters mailed to parents – all expressed some
awareness of the inherent scientific uncertainty of their child’s
CMA result:
B…they were also very clear that they weren’t saying
that [child] is the way that she is because of this extra
material….^ (Participant 7)
BThey were just saying we might not be able, that it
could or could not affect, that there’s no 100 % on
anything….^ (Participant 11)
The rarity of the findings and lack of information available
regarding the particular genetic variants were factors recalled
by parents, with several specifically mentioning the doctor/
genetic counselor reporting uncertainty about whether the
VUS was related to their child’s symptoms due to a lack of
reported cases.
Impact of Results
Participants described a wide variety of emotions when first
receiving or discussing CMA results. Among the most com-
mon responses noted were relief (n=6) and guilt (n=4), with
others reporting comfort, happiness, surprise, disappointment,
sadness, frustration, fear, worry, and mixed emotions. Three
parents initially reported not having significant emotional re-
actions, but at other points in the interview discussed having
emotional responses to receiving the results. One mother de-
scribed how she and her husband reacted to the information
after their appointment:
BIt’s just kind of that moment when you just can’t even,
you’re thinking about it, and you’ve processed so much,
and you just kind of want to sit down and have a drink
and… just be sad for a few minutes. That this is… what
you’re dealing with, basically. Not because you’re re-
sentful, not because you’re feeling sorry for yourself or
anything like that… Normal kids don’t have to go
through this… You just wish for some normalcy for
your kids, you wish for some normalcy for what they’re
gonna have to go through….^ (Participant 7)
Some parents – regardless of whether CNVs were de novo,
inherited, or unknown – expressed strong feelings of guilt
about having passed on the genetic changes or having caused
their child’s health concerns:
B…As a parent, what did we do? What did I do during
my pregnancy? …Was there anything we could have
done to have prevented this? Did we cause it?^ (Partic-
ipant 2)
Table 2 Characteristics of Participants (N=14)
Number Percentagea
Patient’s Age
3–4 years 4 29
5–10 years 7 50
11–19 years 3 21
Patient’s Gender
Female 7 50
Male 7 50
CNV Inheritanceb
De Novo 2 13
Maternal 5 33
Paternal 1 7
Unknown 7 47
Number of Months between Results Disclosure and Interview
1–3 4 29
4–8 7 50
9–15 3 21
Parent’s Gender
Female 13 93
Male 1 7
Parent’s Race
White 11 79
Black/African American 2 14
Native American 1 7
Parent’s Highest Level of Education Completed
Less than High School Diploma 1 7
High School Diploma 2 14
Some College 5 36
Associate’s or Technical Degree 3 21
Bachelor’s Degree 2 14
Graduate Degree 1 7
aNumbers may not add up to 100 % due to rounding
bOut of 15, as one patient had two CNVs with different inheritance
patterns
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Some commented on the permanence of receiving genetic
test results despite the uncertainty of the interpretation, reveal-
ing feelings of sadness or loss for themselves and/or their
children. Others expressed pessimism, hopelessness, and feel-
ings of failure because of the inability to find more specific
information about the cause of their child’s health issues.
When asked about how she felt this genetic testing impacted
her outlook on her child’s medical care, one mother
responded:
BJust kind of feeling like you’re never going to have just
the right answer… your kid’s never going to fit into just
one box. So nobody’s ever going to know what to do
with her. Nobody’s ever going to be able to help because
she doesn’t – she has this abnormality, but it’s not this
disorder that she has or whatever.^ (Participant 7)
Some participants discussed the idea that having a rare
genetic variant made their child unique. Some parents viewed
this as isolating, noting a lack of others who understood their
situation:
BBasically what I’m trying to say is there are support
groups for Down’s [sic] syndrome, there are support
groups for your kid being on the spectrum of autism,
but there’s not a support group for Xq25. There’s not
that many out there to communicate with the other par-
ents, like, ‘Hey, yeah, this is what we’re going through,
this is what seems to help us to cope on those days that
our child is having a bad day.’^ (Participant 8)
Four parents, when asked about the effects of undergo-
ing testing, responded that nothing had changed in their
child’s lives (though 2 of these 4 discussed perceived
benefits of testing later in the interview). Among others,
two main areas of perceived benefits emerged: access to
services (n=6) and information for themselves, health
care providers, teachers, and/or family (n=12). Several
parents received referrals that either identified or ruled
out additional health concerns. Some were connected with
speech, physical, or occupational therapists and/or multi-
disciplinary clinics, and a few claimed that the results had
helped other outside providers make medication deci-
sions. Some anticipated that having test results might as-
sist with financial resources like supplemental social se-
curity income. Many commented that simply having a
result, whether diagnostic or not, facilitated the consider-
ation of more therapeutic options by health care providers
and teachers:
BI don’t want to say they necessarily treat him different-
ly, but I think that now that we have the diagnosis,
they’re so much more open to my suggestions and my
thoughts and they seem a lot more willing to [say], ‘Ok,
well, we’ll try this therapy out….’^ (Participant 2)
Some parents reported a difficult emotional reaction to the
uncertainty surrounding the VUS; others described the benefit
of having Ba point of reference^ or Bsomething to go on.^
Several parents whose children had developmental and/or be-
havioral problems reported being relieved to finally have
some indication of a potential cause. This was particularly
evident in parents who reported prior frustration due to a lack
of support from health care providers, family, and others.
When asked how their feelings about test results had changed
over time, several mentioned an emerging sense of validation
(n=7):
BThe biggest thing to me was just a relief that I’m not
crazy, I’m not a bad mom, that there was something
going on with my son. And I think that the biggest thing
that I have gained from seeing you guys is the relief that
finally, someone, in essence, almost kind of believes me
because of the trouble that we had had for the years
before that^ (Participant 2).
While negative coping was frequently noted, some parents
indicated positive adaptation. Many were grateful that their
child did not have more severe health concerns. When
prompted to discuss how they had continued with their child’s
medical journey after receipt of their genetic test results, sev-
eral parents described engagement as a coping mechanism,
mentioning feelings of empowerment as they became in-
volved in medical management or advocacy. Somementioned
joining support groups and connecting with others after re-
ceiving genetic test results. While a few were hopeful that
technology would provide future options, most acknowledged
that the results, despite being ambiguous, had moved them
toward accepting their child’s conditions:
BLet’s be honest, our genetics, this diagnosis means
that… really things are the way they are… This is very,
very permanent. This is more about acceptance and just
trying to figure out how we can help him… it’s in his
DNA, this isn’t something that’s gonna be changed.^
(Participant 12)
Parental Interpretation
When asked to elaborate on personal interpretations of the
CMA results, many parents described struggling to derive
meaning and blamed this difficulty on a lack of information.
Others were conflicted and/or contradicted themselves. Recur-
ring throughout the interviews were the perceptions of the test
result as an answer (n=3), not an answer (n=2), or in some
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cases, both (n=4). Others did not describe the results as either
an answer or lack thereof, and instead used more ambiguous
descriptions.
Furthermore, parents made a distinction between results as
answers versus explanations for their child’s medical prob-
lems. As an answer, some expressed that the variant, despite
uncertainty about pathogenicity, was a first step toward a uni-
fying diagnosis. As an explanation, parents instead voiced
dismay that little clarification was provided. Prognostic uncer-
tainty was a recurring theme. Ten parents discussed the lack of
substantive information, including not knowing what to ex-
pect developmentally, whether a risk existed for associated
health problems, how to provide helpful medications or ther-
apies, or how to plan for potential long term care:
BI’m not saying they never gave me any answers. What-
ever answer they can provide me, yes, they were excel-
lent giving me that. It’s just that, as a parent of any child,
you want answers for what’s going on with your child.
And if you don’t have answers, [laughter] and if they
don’t have answers, it’s frustrating for everybody….^
(Participant 8)
BUnfortunately, in our case, we didn’t really get an an-
swer, but at least we got an answer that there was some-
thing wrong genetically, but… there wasn’t much infor-
mation on what was wrong….^ (Participant 2)
Several parents, while able to express an accurate under-
standing of the clinical uncertainty associated with their result,
reported feeling confident that the VUS provided a causal
explanation for their child’s health issues (n=7). Some ac-
knowledged this discordance, admitting that they had little
justification for this view other than instinct:
B…She’s got some type of genetic problem, so that’s the
reason why she’s not learning or talking or walking and
doing things that a normal 3 and half year old would do.
…It’s the only explanation I have, so I just have to go
with it. [laughter] I don’t know what else it could be.
I’ve been to so many other doctors and nobody can find
anything, and this is the only thing that they’ve found,
so I just have to believe that this is why [she has] all
these problems.^ (Participant 13)
Some parents associated the CMA result with some, but
not all, of their child’s medical problems – especially those
identified subsequent to the test results – as a consequence of
recommended evaluations (e.g., echocardiograms, ophthal-
mologic exams):
BThe things we found out afterwards, that explains all
those, ‘cause we checked because of that information.
But why is it all in one little tiny body? No, I don’t
know, but I don’t really know that anybody does.^ (Par-
ticipant 11)
Those who did not interpret the CNV as an answer some-
times justified this by citing a lack of information. For exam-
ple, when asked if it explained her child’s health issues, one
mother responded:
BOh no, it didn’t. …Because there were no solutions.
There wasn’t anything definite.^ (Participant 6)
Some parents had developed other causal explanations for
their child’s conditions, including those that were idiopathic or
of an environmental etiology, and therefore had dismissed the
CMA result as irrelevant:
BI really don’t feel like how he speaks has anything to do
with the chromosome duplication; I do believe that has
to do with his ears.^ (Participant 12)
Two parents viewed the CMA result as providing helpful
prognostic information but did not provide detail about what
specifically was helpful. One parent voiced both perspectives;
the results had yielded helpful prognostic information and,
later, lacked such information:
BIt did impact his health, now that we knowwhat to look
out for, what to watch out for and how to work with him
to benefit his life a lot better because we got these
results.^ (Participant 8)
However, later in the interview, the same mother said:
BYou don’t know what’s going to happen the next day,
because there’s nothing to fall back on with answers and
stuff, and what his body is going to be like in 5 years,
because they don’t know anything.^ (Participant 8)
Genetics Follow-up
Plans for future care and management were also explored.
Although 12 of 14 parents indicated motivation to return for
future follow-up in the genetics clinic, not all had an accurate
understanding of the aspects of such a return visit. Some par-
ents correctly recalled that the visit would include a physical
and developmental evaluation in addition to determining
whether new information about the VUS was available (n=
4). Some assumed the doctor/genetic counselor would call
whenever new information became available. Many discussed
having their child Btested again;^ some spoke specifically of
future clinical tests (e.g., whole exome sequencing), while
others discussed the possibility of repeating the CMA. A
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recurring misconception was the expectation that the genetics
laboratory was holding a DNA sample that would be tested
automatically as new technology became available:
BFrom what I understand, as new channels of testing
become available, they’re going to run her blood
through that and test for those things. If anything pops
up, then we’re going to go back and kind of go from
there.^ (Participant 7)
Many parents described confidence in their provider’s ex-
pertise and expected the genetics team to play a future role in
their child’s health care (n=5). The majority expressed an
understanding that in time the significance and implication
of the variant would likely be elucidated. Most were hopeful
and optimistic that their questions would eventually be an-
swered (n=8); however, some worried that Bbad news^ about
their child’s prognosis would be forthcoming (n=2). Most
comments were framedwith an expectation that the ambiguity
surrounding the test result would be resolved (n=8):
BThese tests are going to be just breaking through, left
and right, in the next year at the latest. So, I’m really
excited for that.^ (Participant 9)
BMaybe it will [explain the medical issues] down the
line when they find out what it means to have the extra
material on chromosome 8.^ (Participant 6)
Discussion
This study explored the experiences of families whose chil-
dren had variants of uncertain significance identified through
CMA analysis. The results provide answers to the very impor-
tant questions raised by Fanos in her 2012 commentary: how
well do parents understand microarray, genome, and exome
sequencing results, and how do parents cope with the ambi-
guity and uncertainty of such results (Fanos 2012)? In our
study, we discovered variability in several domains, including:
parental recall and understanding; the impact of results on
health, education, and therapeutic management; and parental
interpretation. However, we also identified several emerging
themes, including parental focus on personally meaningful
rather than technical details, similarities in emotional re-
sponses to a VUS compared to a definitive diagnosis, and
contradictions in personal results interpretation. Parents’ in-
tentions to comply with recommended follow-up were also
investigated, and we noted strong motivation to do so, but
with some misunderstanding of key components of this pro-
cess. Our findings support those of previous studies which
indicated incomplete comprehension and struggles with per-
sonal interpretation of results (Jez et al. 2015; Reiff et al.
2012), and further contribute to the literature surrounding pa-
tient understanding, interpretation and adaptation to genetic
results of uncertain significance.
Parental Recall of Information
Many parents in our study struggled to describe the purpose of
CMA analysis and could not recall what was being interrogat-
ed by the test. Several could not remember specific details
about their child’s VUS, although most were able to correctly
recall whether a deletion or duplication of material was found.
All parents could recount the uncertainty surrounding the
CMA result, although the specific terminology (VUS) was
rarely remembered. Factors contributing to uncertainty were
also recalled, e.g., rarity and lack of clinical information.
These findings support the premise that parents do not find
information about the CMA analysis and the specifics of the
variant identified particularly salient, and therefore do not
retain it over time, despite the fact that these details are
included in pretest counseling, informational materials, and a
letter summarizing the results. Whitmarsh et al. (2007) sug-
gested that even with time, additional information, and inter-
actions with providers, a parent’s understanding of the genet-
ics of a diagnosis remains abstract. Furthermore, the use of
technical language can contribute to confusion and misunder-
standing, resulting in a negative experience (Ashtiani et al.
2014). This raises the essential question of what information
is truly relevant to patients and families and how it is best
presented. Technical details and specific terminology may
best be avoided in favor of a more thorough discussion of
broad concepts, allowing for greater emphasis on psychoso-
cial issues (e.g., unmet expectations, emotional adjustment), a
fundamental tenet of genetic counseling.
Impact of Results
Findings from our study suggest that receiving a VUS result
may have an impact similar to that of receiving a definitive
diagnosis; it was often viewed as an Banswer,^ albeit a more
complicated one. Parents described emotional responses rang-
ing from strong feelings of guilt, sadness, and a sense of loss.
Others described an evolution in their responses to that of
comfort and relief. Some parents reported positive coping
through engagement with support groups or advocacy activi-
ties. Others discussed that the test results empowered them to
seek out medical, educational, therapeutic, and financial ser-
vices. Similar benefits of receiving results were also noted in
previous studies (Jez et al. 2015; Reiff et al. 2012; Whitmarsh
et al. 2007). This suggests that even in the face of ambiguity,
endorsing a parental perspective of active engagement with
healthcare providers, teachers, and others, as well as accessing
resources, can help to facilitate adaptation and coping.
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Uncertainty itself can have emotional consequences; paren-
tal anxiety, depression, and/or helplessness have been reported
in parents when confronting the uncertain nature of their
child’s condition (Lipinski et al. 2006). In fact, some parents
in our study reported difficulties with adapting to their child’s
result and engaged in negative coping such as pessimism,
hopelessness, and feelings of failure. Lipinski et al. (2006)
found that parents of children with chromosome abnormalities
generally had high levels of uncertainty and felt that they had
little control over their child’s condition. We therefore propose
that in many ways, parental reactions to receiving a VUS are
even more complex and have the potential to be more emo-
tionally charged with feelings of loss of control. Post-test ge-
netic counseling for a VUS should acknowledge such re-
sponses and incorporate their possibility into the discussion
of uncertainty to help facilitate parental coping. Results from
our study and others suggest that encouraging parents to seek
out services after receiving a VUS result may facilitate posi-
tive coping and promote feelings of control.
Parental Interpretation of Results
Similar to confronting a diagnostic result, parents in our study
sought to personalize the meaning of the VUS for their child
and family. According to Lazarus and Folkman’s (1987)
Transactional Model of Stress and Coping, this process in-
volves an assessment of the impact a diagnosis will have on
daily life, followed by consideration of what can be done
(Lazarus and Folkman 1987). We found that many parents
struggled with this adaptive process and postulate that it was
in part due to the contradictory nature of their personal views
of the results. Especially intriguing were the recurring oppos-
ing statements about parental interpretation of the VUS as an
Banswer^ but not an Bexplanation^ and vice versa. Further-
more, while some parents made statements indicating ac-
knowledgment of uncertainty, they also asserted feelings of
more certainty about pathogenicity, expressing that the VUS
was Ba point of reference^ or Bsomething to go on.^ This was
also seen in the Vos et al. (2008) study in which patients who
had a VUS in BRCA1/2 were more likely to personally inter-
pret their results as pathogenic, even while correctly recalling
that a VUS had been identified; Vos et al. questioned whether
this was due to a disconnect between recall and perception or
whether it was influenced by other beliefs.
We propose that it may be easier for some families to
categorize ambiguous results in a more conclusive manner
for purposes of coping and adaptation. In fact, the percep-
tion of permanence regarding results was described by
some parents, indicating perhaps acceptance and/or the per-
ception that a genetic variant was the equivalent of a diag-
nosis. Others expressed that their perceptions were instinc-
tive or even based on hope, perhaps reflecting a strong
desire for answers. A recent study reported that many
parents viewed a VUS as having provided an explanation
and therefore had experienced relief (Jez et al. 2015), a
sentiment echoed by some participants in this study. Of
course, the harm in this personal interpretation would be
the possibility that families may not pursue additional
follow-up evaluation, potentially preventing the establish-
ment of a definitive diagnosis and/or the necessity for re-
adaptation should an alternative diagnosis be made. In this
study population, these types of categorizations did not
seem to negatively impact the maintenance of a connection
with the genetics team, as most all respondents clearly stat-
ed their intention to return for follow-up. For some, main-
taining an effective separation between cognitive and emo-
tional perceptions of variants of uncertain significance is
feasible.
Reiff et al. (2012) found that parents held inconsistent
views about their child’s CMA result (whether a definitive
pathogenic result or a VUS) supporting the perception it had
helped them to know what to expect, while also acknowledg-
ing a lack of prognostic information. In our study, some of
those who endorsed the perception that the VUS was not the
cause of their child’s medical problems also expressed incon-
gruous feelings of personal validation. We suggest that, for
these parents, the VUS confirmed their belief that something
was different about their child, yet they could not characterize
the VUS as causal due to the lack of clarifying and prognostic
information.
Importantly, some parents made statements in support of
the positive nature of uncertainty, voicing the idea that hav-
ing a VUS made their child unique. Others found this iso-
lating, reminiscent of the early experiences of families of
children diagnosed with rare disorders described in the
Fanos (2012) commentary. This is concerning given the like-
lihood of a growing frequency of ambiguities and difficulties
with results interpretation in the era of advancing genetic
technology. Clearly, individuals have varying tolerances to-
ward uncertainty, some of which may relate to their views
about genetic testing and/or healthcare, in general (Biesecker
et al. 2014). This highlights the importance of pretest
counseling that includes promoting a view of the evaluation
process that is more open-ended rather than linked to a ge-
netic test result. Whitmarsh et al. (2007) noted that amid the
medical expertise associated with a genetic diagnosis, fami-
lies who value their own experiences and adopt an open
approach, emphasizing their child’s individuality, are under-
taking important processes that result in a valuing of the
unknown. Including a discussion about the possibility of
uncertainty in genetic testing and results – from the clinical
significance of a CNV to the prognostic limitations of even
well-defined syndromes – prior to testing, rather than focus-
ing on an attempt to reduce uncertainty through diagnostic
testing, may help parents form more realistic expectations
regarding the outcomes of testing.
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Genetics Follow-Up
Previous studies of genetics follow-up havemostly focused on
medical management for known genetic disorders, such as
screening for cancer predisposition syndromes (Schneider
and Schmidtke 2014). We were therefore particularly interest-
ed in examining parental responses to queries about their in-
tention to comply with recommended follow-up in pediatric
genetics in the setting of a VUS. Palmer et al. (2014) recently
reported that a significant number of VUS identified in 2010
had been reclassified as Bpotentially pathogenic^ or as a
Bsusceptibility or modifier CNV^ just 2 years later. We feel
it imperative that genetics professionals emphasize the impor-
tance of a follow-up genetics evaluation to allow for a review
of available databases, the literature, and a re-evaluation of the
patient. Otherwise, families may be lost to follow-up and miss
updated information that could impact their child’s health
care.
We found that, despite differing interpretations of the VUS
as an answer but not as providing any clarification, the recom-
mendation and importance of follow-up were accurately
recalled, and all parents expressed intentions to do so. Inter-
estingly, the majority of participants expressed the belief that
the significance of the VUS would be elucidated and that
eventually their questions would be answered. However, some
parents were confused about the follow up process. Some
believed that the geneticist/genetic counselor would automat-
ically initiate contact once new information regarding their
child’s VUS became available. This confusion occurred de-
spite explicit statements made during clinic visits and in sum-
mary letters recommending a return visit after a specified pe-
riod of time (usually 1–2 years). Clearly, this highlights the
need to further improve communication. We have addressed
this in our clinic since this study by designing a brief patient/
family education sheet provided as a supplement to pretest
counseling that includes a statement about the possibility of
a VUS requiring follow-up and potentially further testing.
Study Limitations
This study has a number of limitations. Due to a limited num-
ber of eligible subjects, piloting of the interview guide was
only possible on a small sample of pediatric genetic coun-
selors. The study population was also limited to one medical
center and subject to self-selection bias, and therefore the re-
sults are not generalizable to all populations undergoing
CMA. The small sample size limited the ability to make com-
parisons between groups within the sample; e.g., established
patients who had undergone pretest counseling versus those
who had CMA ordered by an outside provider, VUS which
were determined to be de novo versus inherited. Inconsis-
tencies between and within these groups also included results
disclosure, with some being contacted by phone by Pediatric
Genetics staff with variable amounts of information discussed
prior to the in-person CMA counseling appointment, and
others being told they would review all information at the time
of their genetics appointment. Due to a desire to focus on
issues related to genetic uncertainty and given limited re-
sources, this study did not recruit parents of children who
had clearly pathogenic or normal CMA results, resulting in
the inability to make direct between-group comparisons.
However, our study identified themes that appear to be similar
to those expressed by parents receiving pathogenic results.We
also acknowledge that retrospective attempts to elicit memory
of genetic counseling sessions are subject to recall bias. Fur-
thermore, the scope of our study did not allow us to determine
whether participants had successfully completed follow-up
per our recommendations.
Conclusions
Chromosomal microarray analysis is a powerful diagnostic
tool, resulting in the identification of new syndromes and
expanding understanding of the phenotypic spectrum of pre-
viously described disorders. However, interpretation of CMA
results can be problematic, as there is a significant likelihood
of identifying a copy number variant of uncertain significance.
This presents challenges for parents who have been seeking a
diagnosis for their child. Genetic providers need to address the
lack of available information and help parents identify effec-
tive coping strategies. These challenges will only increase as
genomic sequencing is implemented as a clinical diagnostic
tool and sequence variants for which little or no information
exists are identified. Furthermore, it is likely that the gap be-
tween identification and interpretation will grow in the fore-
seeable future as utilization increases due to decreasing costs
of sequencing (Cutting 2014).
While the findings reported here were collected from a
study of CMA results, they may also apply to other genome-
wide diagnostic tools currently being implemented in clinical
genetics and other medical specialties which also have the
potential to identify findings of uncertain clinical significance.
Our results reinforce the value of pre- and post-test genetic
counseling and suggest that results disclosure of a VUS
should be similar in many ways to returning a definitive ge-
netic test result. While communicating relevant information, it
is critical to attend to emotional responses and explore how
parents integrate genetic information into their view of their
child’s illness. In order to effectively facilitate parental coping
and adaptation, genetics professionals should be prepared for
a wide range of reactions and personal interpretations. Endors-
ing an open-minded approach to their child’s future in the face
of uncertainty may be particularly beneficial. Furthermore, it
is important that parents clearly understand the importance of
follow-up, and this may require multiple explicit reminders.
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